Prevalence of Cardiometabolic Disease Risk Factors in People With HIV Initiating Antiretroviral Therapy at a High-Volume HIV Clinic in Kampala, Uganda.
Prevalence of Cardiometabolic Disease Risk Factors in People With HIV Initiating Antiretroviral Therapy at a High-Volume HIV Clinic in Kampala, Uganda.
复制标题
DOI:
10.1093/ofid/ofad241
复制
发表时间:
2023-06
影响因子:
4.2
通讯作者:
中科院分区:
文献类型:
--
作者:
Cardiometabolic diseases are a leading cause of HIV-related morbidity and mortality, yet routine screening is not undertaken in high-burden countries. We aimed to assess the prevalence and risk factors of the metabolic syndrome (MetS) and its components in adult Ugandan people with HIV (PWH) initiating dolutegravir-based antiretroviral therapy (ART). We conducted a cross-sectional study using baseline sociodemographic and clinical data of PWH aged ≥18 years enrolled in the Glucose metabolism changes in Ugandan HIV patients on Dolutegravir (GLUMED) study from January to October 2021. MetS was defined as having ≥3 of the following: abdominal obesity, hypertension (HTN), hyperglycemia, elevated triglycerides, and low high-density lipoprotein cholesterol. Multiple logistic regression was used to assess associations between potential risk factors and MetS and its components. Three hundred nine PWH were analyzed (100% ART-naïve, 59.2% female, median age 31 years, and median CD4 count 318 cells/mm3). The prevalence of MetS was 13.9%. The most common cardiometabolic condition was dyslipidemia (93.6%), followed by abdominal obesity (34.0%), hyperglycemia (18.4%), and HTN (8.1%). In adjusted analysis, MetS was associated with age >40 years (adjusted odds ratio [aOR], 3.33; 95% CI, 1.45–7.67) and CD4 count >200 cells/mm3 (aOR, 3.79; 95% CI, 1.23–11.63). HTN was associated with age >40 years (aOR, 2.96; 95% CI, 1.32–6.64), and dyslipidemia was associated with urban residence (aOR, 4.99; 95% CI, 1.35–18.53). Cardiometabolic risk factors were common in this young Ugandan cohort of PWH initiating dolutegravir-based ART, underscoring the need for programmatic implementation of surveillance and management of comorbidities in Uganda and similar settings.
登录
查看更多内容
影响因子:
3.7
作者:
通讯作者:
--
影响因子:
4.6
作者:
Achhra AC;Lyass A;Borowsky L;Bogorodskaya M;Plutzky J;Massaro JM;D'Agostino RB Sr;Triant VA
通讯作者:
Triant VA
影响因子:
--
作者:
Brown, TT;Cole, SR;Dobs, AS
通讯作者:
Dobs, AS
影响因子:
4.6
作者:
Harimenshi, Deo;Niyongabo, Theodore;Preux, Pierre-Marie;Aboyans, Victor;Desormais, Ileana
通讯作者:
Desormais, Ileana
影响因子:
3.7
作者:
Bavinger C;Bendavid E;Niehaus K;Olshen RA;Olkin I;Sundaram V;Wein N;Holodniy M;Hou N;Owens DK;Desai M
通讯作者:
Desai M